Master chest CT protocol optimization for pneumonia diagnosis. Learn GGO patterns, consolidation, COVID-19 Omicron variant imaging 2026, Long COVID cardiopulmonary sequelae, low-dose protocols, and AI-enhanced detection.

7 Critical Chest CT Protocol Steps for Pneumonia Diagnosis, COVID-19 Variants & Long COVID Sequelae

1. Introduction: why chest CT remains indispensable in pneumonia diagnosis

Pneumonia remains a leading cause of global morbidity and mortality, with accurate imaging essential for timely diagnosis and management. Chest computed tomography surpasses chest radiography in sensitivity and detail, revealing characteristic patterns such as ground-glass opacities, consolidation, crazy-paving, tree-in-bud, halo, and reverse halo signs across bacterial, viral, and fungal etiologies.^[1-3] This comprehensive review synthesizes evidence on CT findings, scanning protocols (including ultra-low-dose techniques), diagnostic performance (sensitivity typically 95–99%, specificity variable due to overlaps), pediatric applications, complications, and differential diagnosis. Special focus is given to COVID-19: acute patterns (bilateral peripheral ground-glass opacities), evolution in 2026 Omicron subvariants (milder, more atypical features with less consolidation), and Long COVID sequelae (persistent pulmonary ground-glass opacities and fibrosis in 30–70% at 6–12 months, declining ground-glass opacities but stable fibrosis up to 36 months; cardiac inflammation via PET/MRI in approximately 57% with myocarditis or pericarditis-like changes).^[4-6] Advances in AI-enhanced low-dose CT and multimodal imaging (PET/MRI for inflammation) are discussed. Evidence draws from systematic reviews, meta-analyses, and studies through early 2026.

Pneumonia, an acute inflammatory condition of the lung parenchyma, is predominantly infectious and ranks among the top causes of death worldwide, with millions of cases annually.^[1] Community-acquired pneumonia affects adults and children, while hospital- and ventilator-associated forms add complexity. Major pathogens include bacteria (Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus), viruses (influenza, SARS-CoV-2), fungi (Aspergillus spp., Pneumocystis jirovecii), and atypicals (Mycoplasma pneumoniae, Legionella). The global burden of lower respiratory infections, including pneumonia, was estimated by the GBD 2019 study to account for over 2.5 million deaths annually, with disproportionate impact in low- and middle-income countries and among vulnerable populations such as the elderly, immunocompromised, and those with chronic cardiopulmonary disease.^[7]

Diagnosis relies on a multimodal approach: clinical presentation (fever, cough, dyspnea, pleuritic pain), laboratory markers (leukocytosis, CRP, procalcitonin), microbiology (sputum/PCR), and imaging. Imaging confirms parenchymal involvement, assesses extent and severity, identifies complications (abscess, empyema, necrosis), and guides therapy while differentiating mimics (pulmonary edema, hemorrhage, malignancy).^[2] The integration of imaging with clinical and laboratory data is essential for accurate diagnosis, as no single modality provides definitive etiologic identification. Radiological patterns, while suggestive, require correlation with epidemiological context, host immune status, and microbiological confirmation for optimal patient management.

Chest radiography serves as the traditional first-line modality due to low cost, availability, and minimal radiation (effective dose approximately 0.1 mSv). However, chest radiography sensitivity is limited (50–70% for confirmed pneumonia), often missing early, subtle, or posteriorly located disease, leading to occult pneumonia in 20–50% of clinically suspected cases, especially in immunocompromised or elderly patients.^[2,3] A landmark study by Self et al. (2013) demonstrated high discordance between chest radiography and CT for detection of pulmonary opacities in emergency department patients, with CT revealing pneumonia in a substantial proportion of patients with negative or equivocal chest radiographs.^[8] This diagnostic gap has significant clinical implications, as missed pneumonia can lead to delayed antibiotic therapy, progression to severe disease, and increased mortality.

Chest CT, particularly high-resolution CT, provides superior spatial resolution, multiplanar reconstruction, and thin-slice capability, detecting abnormalities overlooked on chest radiography in 30–50% of cases.^[3] Key CT patterns include ground-glass opacities (hazy increased attenuation without obscuring underlying vessels or bronchi, reflecting partial alveolar filling or interstitial thickening); consolidation (homogeneous opacity completely obscuring vessels and bronchi, indicating dense alveolar filling); crazy-paving (superimposed interlobular septal thickening on ground-glass opacities, resembling irregular paving stones); tree-in-bud (centrilobular small nodules with branching linear opacities, mimicking budding trees and indicating endobronchial spread); halo sign (ground-glass opacity surrounding a nodule or mass, often due to hemorrhage or angioinvasion); and reverse halo or atoll sign (central ground-glass opacity with peripheral consolidation ring, seen in organizing pneumonia or invasive fungal disease). These patterns offer etiologic clues despite significant overlap.^[1,3]

The COVID-19 pandemic dramatically increased CT utilization, revealing characteristic bilateral peripheral and multifocal ground-glass opacities with basal predominance.^[4] As of July 2026, Omicron subvariants (e.g., XFG approximately 53% prevalence) dominate, showing generally milder radiographic severity with more atypical distributions and fewer consolidations compared to earlier strains.^[5,6] The pandemic also catalyzed rapid advances in low-dose CT protocols, AI-assisted detection, and quantitative imaging biomarkers that have transformed the broader landscape of pneumonia imaging beyond COVID-19 alone.

2. Imaging modalities in pneumonia diagnosis

Chest radiography

Chest radiography detects lobar or segmental consolidation, silhouette sign, pleural effusions, and cavitation affordably and quickly. It remains first-line in resource-limited settings and outpatient care. Limitations include low sensitivity for subtle ground-glass opacities, early disease, or dependent and posterior lesions, with specificity approximately 70% due to overlap with non-infectious processes (e.g., atelectasis, edema).^[2] Occult pneumonia (CT-positive, chest radiography-negative) occurs frequently in immunocompromised hosts or atypical infections.^[3] The interobserver reliability of chest radiography in community-acquired pneumonia is moderate at best, with substantial variation in interpretation of infiltrate extent, presence of effusion, and cavitation, further limiting its diagnostic precision in complex cases.^[9]

In patients with acute exacerbation of chronic obstructive pulmonary disease, chest radiography misses pneumonia in up to 30% of cases where CT subsequently confirms infection.^[10] This diagnostic failure mode is particularly dangerous because COPD patients with superimposed pneumonia have significantly higher mortality and require more aggressive therapeutic interventions. The decision to escalate from chest radiography to CT should be guided by clinical suspicion, disease severity, and risk stratification rather than protocol alone.

Lung ultrasound

Lung ultrasound has emerged as a valuable bedside tool, especially in critical care and pediatrics. It identifies subpleural consolidations, B-lines (interstitial syndrome), pleural effusions, and dynamic air bronchograms with sensitivity 90–98% and specificity approximately 90% for bacterial pneumonia, often outperforming chest radiography.^[7] Advantages include no radiation, real-time assessment, and portability. Limitations include operator dependence and poor penetration in obese patients or deep lesions. The technique is particularly valuable in pediatric populations where radiation avoidance is paramount and in critically ill patients where transport to CT poses significant risks.

Magnetic resonance imaging

Magnetic resonance imaging avoids ionizing radiation and excels in soft-tissue contrast, showing promise in pediatric pneumonia for detailed evaluation without radiation exposure. It detects consolidations, effusions, and lymphadenopathy but is hindered by long scan times, motion artifacts, cost, and limited availability.^[7] Emerging rapid MRI sequences with free-breathing acquisition and motion correction algorithms may expand its role in select populations, though CT remains the workhorse for acute pneumonia assessment.

Chest computed tomography

CT is the reference standard for pulmonary infection imaging. It provides exquisite parenchymal detail, early detection of ground-glass opacities and consolidation, complication identification (necrosis, abscess, empyema), and alternative diagnosis exclusion (e.g., malignancy, vasculitis). Non-contrast high-resolution CT optimizes interstitial and parenchymal assessment; contrast-enhanced CT delineates vascular complications, necrosis, or empyema (split pleura sign).^[3] The ability to detect subtle ground-glass opacities, characterize their distribution, and monitor temporal evolution makes CT indispensable for immunocompromised patients, severe community-acquired pneumonia, and complicated hospital-acquired infection where delayed diagnosis carries substantial morbidity and mortality.

3. Chest CT scanning protocols for pneumonia

Standardized protocols balance diagnostic quality with radiation minimization (ALARA principle), especially relevant for serial and follow-up imaging in pandemics or Long COVID.^[8] Protocol optimization requires careful attention to patient-specific factors including body habitus, respiratory capacity, clinical indication, and prior imaging history. A one-size-fits-all approach inevitably compromises either diagnostic quality or radiation safety.

Non-contrast chest CT

Non-contrast chest CT is preferred for initial parenchymal evaluation. Patient positioning requires supine positioning with arms elevated and full inspiratory breath-hold. The scan range extends from lung apices to costophrenic angles (thoracic inlet to adrenals). Acquisition uses volumetric helical scanning with thin collimation (0.6–1 mm). Tube voltage and current settings are 100–120 kVp (80–100 kVp for pediatric or slim patients) with automatic tube current modulation (reference 40–200 mAs). Pitch and rotation are set to 1–1.5 and 0.5 seconds respectively.

Reconstruction employs high-spatial-resolution lung kernel (B60-B80), 1–1.5 mm axial slices; soft-tissue kernel for mediastinum; multiplanar reformats (coronal and sagittal), maximum and minimum intensity projections. Radiation dose for standard protocols is 3–8 mSv; iterative reconstruction or deep learning reduces this to 1–3 mSv.^[9] The high-resolution CT variant uses interspaced thin slices (1–2 mm every 10–20 mm) for interstitial detail with lower dose. For suspected interstitial pneumonia, diffuse lung disease, or immunocompromised patients with subtle ground-glass opacities, contiguous thin-slice acquisition (1.0–1.25 mm) is essential, as standard 5 mm slices may miss small nodules, early interstitial changes, or subtle ground-glass opacities that represent the earliest radiographic manifestation of opportunistic infection.

Contrast-enhanced chest CT

Contrast-enhanced chest CT is indicated for suspected complications (abscess versus necrosis, empyema, vascular involvement), non-resolving pneumonia, or pulmonary embolism suspicion. Contrast administration uses 80–120 mL non-ionic iodinated contrast (300–350 mgI/mL) at 3–4 mL/s injection rate. Timing is portal venous phase (55–70 seconds) for parenchymal enhancement; arterial phase for pulmonary embolism protocol. Dual-energy CT is optional for iodine mapping and perfusion defects in Long COVID or vascular sequelae.

The split pleura sign, pathognomonic for empyema, requires adequate contrast enhancement of both visceral and parietal pleural surfaces. Necrotizing pneumonia demonstrates central non-enhancement within consolidated lung, while abscess formation shows rim enhancement with central fluid attenuation. For suspected pulmonary embolism complicating pneumonia, dedicated CTPA protocol with optimized contrast timing is essential, as discussed in our companion article on CTPA protocol optimization.^[11]

Low-dose and ultra-low-dose protocols

Low-dose and ultra-low-dose protocols are essential for follow-up, pediatric, or immunocompromised patients. Ultra-low-dose CT (less than 1 mSv, often 0.2–0.5 mSv) with model-based iterative reconstruction or deep learning denoising achieves 98–99% diagnostic agreement for ground-glass opacities, consolidation, and viral patterns compared to standard-dose.^[9,10] The 2025 multisociety consensus recommends low-dose (1–3 mSv) for post-COVID residual abnormality assessment; ultra-low-dose (less than 0.5 mSv) is not routinely advised for subtle ground-glass opacity evaluation due to potential noise.^[11]

Deep learning reconstruction algorithms represent a paradigm shift in low-dose CT imaging. Unlike traditional iterative reconstruction, which trades noise reduction for potential texture alteration, deep learning networks trained on high-dose reference images can restore low-dose acquisitions to near-reference quality while preserving fine parenchymal detail essential for pneumonia detection. A 2025 study by Slasky and Walker demonstrated that denoised ultra-low-dose chest CT maintained diagnostic accuracy for pneumonia detection in immunocompromised patients at doses below 0.5 mSv.^[10]

Supplemental techniques include expiratory scans for air trapping and prone positioning for dependent changes. Prone imaging is particularly valuable for differentiating true dependent consolidation from atelectasis, as true pneumonia persists whereas atelectasis shifts or resolves with positional change.

4. CT patterns by pathogen: a radiologist’s pattern recognition guide

Pattern recognition on chest CT provides powerful etiologic clues, though significant overlap between infectious and non-infectious processes necessitates correlation with clinical context, laboratory markers, and microbiological data. The following framework organizes common patterns by typical pathogen category while acknowledging the substantial overlap that characterizes real-world practice.

Bacterial pneumonia

Bacterial pneumonia classically presents with lobar or segmental consolidation, often homogeneous with air bronchograms. Streptococcus pneumoniae produces single-lobe involvement, most commonly in the lower lobes, with air bronchograms visible in 50–80% of cases. Klebsiella pneumoniae demonstrates the bulging fissure sign from voluminous exudate, a classic but relatively uncommon finding. Necrotizing pathogens (Staphylococcus aureus, anaerobes) produce cavitation and abscess formation, with Staphylococcus aureus particularly associated with pneumatocele formation in pediatric populations. Tree-in-bud opacities indicate bronchiolar spread; parapneumonic effusions and empyema are common complications requiring prompt drainage.^[3]

Community-acquired bacterial pneumonia typically shows acute onset consolidation with air bronchograms, while hospital-acquired and ventilator-associated pneumonia often presents with multifocal, patchy, or bilateral consolidation reflecting aspiration and hematogenous spread. The radiographic progression from focal consolidation to diffuse bilateral involvement in severe sepsis carries prognostic significance and should prompt aggressive therapeutic escalation.

Viral pneumonia

Viral pneumonia presents with multifocal, bilateral ground-glass opacities that are predominant (peripheral or peribronchovascular); crazy-paving is frequent. Consolidation is secondary and often indicates organizing pneumonia or superimposed bacterial infection. Influenza produces patchy peribronchovascular opacities with relative sparing of the lung periphery. Adenovirus can produce lobar consolidation mimicking bacterial infection, particularly in children. In immunocompromised patients (CMV, VZV), nodular ground-glass opacities with halos are seen, reflecting hemorrhagic vasculitis. Tree-in-bud opacities appear in viral bronchiolitis, particularly respiratory syncytial virus and parainfluenza in pediatric populations.^[12]

The temporal evolution of viral pneumonia on CT follows a characteristic pattern: early ground-glass opacities (days 1–3) progress to crazy-paving and consolidation (days 5–10), followed by resolution or organization. Failure to improve by day 10 should raise suspicion for superimposed bacterial infection, acute respiratory distress syndrome, or underlying immunodeficiency.

Fungal pneumonia

Fungal pneumonia varies dramatically by immune status. Angioinvasive aspergillosis in neutropenic patients produces nodules with halo sign (hemorrhage surrounding a septic infarct). In the recovery phase, as neutropenia resolves, the air crescent sign appears as the infarcted tissue retracts from viable lung. Pneumocystis jirovecii pneumonia produces diffuse bilateral ground-glass opacities with crazy-paving and cysts, predominantly in the perihilar regions with relative apical sparing in early disease. Endemic fungi (histoplasmosis, coccidioidomycosis, blastomycosis) produce miliary nodules, cavitation, and mediastinal lymphadenopathy. Mucormycosis produces reverse halo in immunocompromised patients, often with rapid progression and angioinvasive behavior.^[13]

Aspiration pneumonia

Aspiration pneumonia demonstrates characteristic dependent distribution, most commonly in the posterior segments of the upper lobes (when supine) and superior segments of the lower lobes. The right lung is more frequently affected than the left due to the more direct alignment of the right main bronchus with the trachea. Findings include patchy consolidation, ground-glass opacities, and tree-in-bud opacities reflecting bronchiolar inflammation. Chronic aspiration may produce bilateral lower lobe fibrosis with bronchiectasis.^[14]

Atypical pneumonia

Mycoplasma pneumoniae produces interstitial and reticular patterns with bronchial wall thickening, centrilobular nodules, and tree-in-bud opacities. Consolidation is less common than in typical bacterial pneumonia. Legionella produces patchy, rapidly progressive consolidation with pleural effusion in 30–50% of cases. The radiographic severity often exceeds the clinical appearance in early disease, making CT particularly valuable for early detection.

5. COVID-19 pneumonia on chest CT: acute patterns, 2026 variants, and Long COVID sequelae

Acute COVID-19 patterns

Acute COVID-19 produces bilateral, peripheral and multifocal round or oval ground-glass opacities that are predominant; basal and peripheral distribution with relative sparing of the central lung. Progression includes crazy-paving, consolidation (often organizing), linear and reticular opacities, vascular thickening, and reverse halo. Peak severity occurs approximately 10–14 days post-onset.^[4,14] The CO-RADS classification system, developed early in the pandemic, provides a standardized categorical CT assessment scheme for patients suspected of having COVID-19, with categories ranging from CO-RADS 1 (very low probability) to CO-RADS 5 (very high probability), facilitating standardized reporting and clinical decision-making.^[15]

Temporal evolution follows a predictable pattern: early ground-glass opacities (days 0–4) progress to crazy-paving and consolidation (days 5–8), peak severity (days 9–13), and gradual resolution or organization (days 14+). Patients who develop organizing pneumonia pattern or fibrotic changes during the acute phase are at higher risk for persistent Long COVID pulmonary sequelae. The chest CT severity score, quantifying the extent of lobar involvement, correlates with clinical severity and short-term prognosis, providing an objective biomarker for triage and resource allocation.^[16]

2026 SARS-CoV-2 variants

Omicron subvariants dominate (XFG approximately 53%, XFG.14.1 approximately 16%, others); increased transmissibility but reduced virulence. Systematic reviews and meta-analyses from 2025 show Omicron-associated pneumonia has more atypical and non-typical features (peribronchovascular, upper-lobe predominance) versus Delta and earlier strains; less consolidation, lower CT severity scores, and more normal scans (37% Omicron versus 15% Delta in some cohorts). No major novel patterns have emerged; overlaps with prior Omicron waves persist.^[5,6,17]

The reduced radiographic severity of Omicron variants has implications for CT utilization in COVID-19 diagnosis. With higher rates of normal or near-normal CT scans, the negative predictive value of CT for excluding COVID-19 pneumonia has decreased compared to earlier variants. This shift reinforces the importance of PCR testing and clinical correlation, with CT reserved for assessment of severity, complications, or alternative diagnoses rather than primary diagnostic confirmation.

Long COVID pulmonary sequelae

Post-acute sequelae affect 10–30% of survivors with persistent respiratory symptoms greater than 12 weeks. Chest CT abnormalities appear in 30–70% at 6–12 months (higher post-severe disease): ground-glass opacities decline over time (32% at 6 months to 20% at 36 months); fibrosis, reticulation, and traction bronchiectasis remain stable and persistent (27–47% up to 36 months).^[17,18] Non-fibrotic changes (bands, heterogeneous attenuation) regress more readily. The 2025 consensus recommends CT for persistent or worsening symptoms of 3 months or more (lasting 2 months or more, no alternative cause); use “post-COVID-19 residual lung abnormality” terminology to avoid conflating with idiopathic interstitial lung disease; prefer low-dose protocols.^[11,19]

Quantitative CT analysis in Long COVID reveals progressive loss of well-aerated lung volume and increased non-aerated and poorly aerated volumes, correlating with restrictive physiology and impaired diffusion capacity. The persistence of fibrotic changes beyond 24 months suggests that a subset of Long COVID patients develop irreversible structural lung damage, raising concerns about long-term respiratory disability and the potential need for antifibrotic therapy in selected cases.

Long COVID cardiac effects

Elevated risk of major adverse cardiovascular events (myocardial infarction, stroke, heart failure, arrhythmia) persists up to 2–3 years post-infection, even in mild cases. Mechanisms include persistent inflammation, endothelial dysfunction, accelerated atherosclerosis, and microvascular injury.^[20,21] Symptoms (palpitations, chest pain, dyspnea) overlap pulmonary sequelae, making multimodal imaging essential for accurate characterization.

Advanced imaging with PET/MRI detects persistent inflammation; 2025 large cohort shows abnormalities in 57%: myocarditis-like (24%), pericarditis (22%), periannular uptake (11%), vascular uptake (aortic and pulmonary, 30%). No uptake is seen in controls.^[22,23] Chest CT’s role includes incidental findings (pericardial effusion, cardiomegaly, coronary calcification). Dual-energy CT assesses pulmonary perfusion defects linked to cardiopulmonary strain. Multimodal imaging (MRI and PET gold-standard for inflammation) is recommended for symptomatic patients; abnormal findings may predict future cardiac and pulmonary disease warranting monitoring.^[24]

6. Pediatric pneumonia on chest CT

Pediatric patterns differ from adults: viral pathogens (RSV, parainfluenza, adenovirus) predominate in younger children, producing bronchial wall thickening, centrilobular nodules, tree-in-bud, and multifocal ground-glass opacities. Bacterial infection produces lobar consolidation with frequent complications (necrotizing pneumonia, abscess, pneumatocele). Mycoplasma produces interstitial and reticular patterns. Round pneumonia, a distinctive pediatric entity, presents as a spherical or ovoid mass-like consolidation, most commonly in the lower lobes, and can mimic malignancy if not recognized.^[25]

CT use is limited due to radiation sensitivity; reserved for complicated, non-resolving, or immunocompromised cases. Low-dose and ultra-low-dose CT are essential; lung ultrasound often serves as first-line.^[7,26] The European Guidelines on Quality Criteria for Diagnostic Radiographic Images in Paediatrics provide specific dose reference levels that should guide protocol optimization, with target doses for pediatric chest CT typically 50–70% lower than adult equivalents for comparable body regions.^[13]

Necrotizing pneumonia is an increasingly detected complication in children, with CT showing non-enhancing areas within consolidation, cavitation, and pneumatocele formation. Early recognition is critical as necrotizing pneumonia may require prolonged antibiotic therapy, drainage, or surgical intervention. The distinction between necrotizing pneumonia and lung abscess on CT can be challenging; necrotizing pneumonia typically shows multiple small cavities within consolidated lung without dominant fluid level, whereas abscess presents as a rounded cavity with air-fluid level and rim enhancement.

7. Complications of pneumonia on chest CT

Key complications detectable on chest CT include necrotizing pneumonia and abscess (non-enhancing areas, cavitation, air-fluid levels within consolidation); empyema (lenticular pleural collection, split pleura sign with enhancing visceral and parietal pleura, loculations); and bronchopleural fistula (persistent pneumothorax with cavity-pleural communication). Contrast enhancement is crucial for differentiation; higher incidence occurs in pediatric bacterial or severe viral and necrotic cases.^[3,26]

Parapneumonic effusions complicate approximately 40% of hospitalized bacterial pneumonia cases. CT distinguishes simple parapneumonic effusion (free-flowing, homogeneous attenuation) from complicated parapneumonic effusion (loculated, septated, heterogeneous) and empyema (thickened, enhancing pleura with split pleura sign). The distinction guides management: simple effusions often resolve with antibiotics alone, while complicated effusions and empyema require drainage (thoracentesis, chest tube, or video-assisted thoracoscopic surgery).^[27]

Pneumothorax complicating pneumonia, particularly in necrotizing pneumonia or mechanical ventilation, requires urgent recognition. CT is more sensitive than chest radiography for small pneumothoraces and can identify bronchopleural fistula as the underlying cause. Tension pneumothorax is a medical emergency requiring immediate decompression; CT should not delay intervention when clinical suspicion is high.

8. Sensitivity and specificity of chest CT

Chest CT sensitivity for pneumonia detection approaches 95–99%, far exceeding chest radiography.^[3] For COVID-19, pooled sensitivity is 87–97%, specificity 46–70% versus RT-PCR (overlap with other viral pneumonias).^[14,28] Ultra-low-dose CT maintains high performance for viral patterns.^[9] High negative predictive value aids exclusion of disease.^[29]

The high sensitivity of CT makes it invaluable for excluding pneumonia in immunocompromised patients with fever of unknown origin, where negative CT can guide de-escalation of empiric antimicrobial therapy. However, the moderate specificity reflects the substantial overlap between infectious and non-infectious processes (pulmonary edema, hemorrhage, organizing pneumonia, drug reaction, malignancy). Clinical correlation, laboratory markers (procalcitonin, CRP), and microbiological confirmation are essential for accurate diagnosis.

For COVID-19 specifically, CT sensitivity exceeds PCR in early disease (days 0–4), when viral loads may be below detection threshold but radiographic changes are already apparent. However, CT specificity is limited because other viral pneumonias (influenza, RSV, adenovirus) and non-infectious processes can produce identical ground-glass opacities. The CO-RADS classification improves specificity by incorporating distribution patterns and clinical pre-test probability.^[15]

9. Recent advances and future directions

Ultra-low-dose CT with deep learning reconstruction achieves near-standard diagnostic quality at minimal dose.^[10] Artificial intelligence enables automated detection (greater than 95% accuracy), severity quantification, and pattern classification (variant-invariant).^[27] Quantitative CT measures lung volume, fibrosis extent scoring, and texture analysis biomarkers. Hybrid imaging with PET/CT or PET/MRI evaluates inflammation in Long COVID. Future directions include AI-driven prognostic models, biomarker integration, and personalized follow-up protocols.

Photon-counting CT, now entering clinical practice in 2026, offers improved spatial resolution, reduced noise, and enhanced iodine contrast at lower dose compared to conventional energy-integrating detectors. For pneumonia imaging, photon-counting CT may improve detection of subtle ground-glass opacities, better characterize interstitial changes, and enable more accurate quantitative assessment of lung parenchyma. Early studies suggest dose reductions of 30–50% are achievable without compromising diagnostic quality.

AI algorithms for pneumonia detection have evolved from simple convolutional neural networks to sophisticated transformer-based architectures that can simultaneously detect, localize, and classify pneumonia patterns while quantifying severity. Integration of clinical data (vital signs, laboratory markers) with imaging features enables predictive modeling of outcomes including need for intensive care, mechanical ventilation, and mortality. These tools, while promising, require rigorous validation across diverse populations and imaging protocols before widespread clinical adoption.

10. The role of contrast media delivery systems in chest CT quality

Underpinning all diagnostic advances is the fundamental requirement for reliable, high-performance imaging infrastructure. The quality of contrast-enhanced chest CT depends critically on the integrity of the contrast delivery system. Air bubbles, inconsistent flow rates, and line failures can produce suboptimal enhancement, motion artifacts, and nondiagnostic studies that compromise patient care and waste resources.

The SATLine patient lines with dual check valves, SATSyringe high-pressure syringes, and multi-use 24-hour sets provide the validated, bubble-free fluid paths and standardized consumables that maintain contrast integrity and protocol consistency across all chest CT applications. The dual-check-valve design prevents backflow and ensures complete air evacuation, eliminating the risk of venous air embolism that can complicate contrast-enhanced imaging. High-pressure syringes rated to 350 PSI accommodate the flow rates required for CTPA and contrast-enhanced chest CT without risk of line failure or extravasation.

Without this foundation of dependable equipment and rigorous quality assurance, even the most sophisticated protocol optimization cannot achieve its diagnostic potential. Standardized consumables reduce variability between studies, between operators, and between shifts, ensuring that every patient receives the same high-quality contrast delivery regardless of when or where their scan is performed.

11. Special populations: tailoring chest CT protocols

Immunocompromised patients

Immunocompromised patients represent one of the highest-yield populations for chest CT in pneumonia evaluation. The differential diagnosis is broad, encompassing bacterial, viral, fungal, and opportunistic infections, as well as non-infectious mimics including drug toxicity, radiation pneumonitis, and malignancy. High-resolution CT with thin contiguous slices (1.0–1.25 mm) is essential, as subtle ground-glass opacities, small nodules, or early interstitial changes may be the only radiographic manifestation of life-threatening infection.^[46]

Neutropenic patients with fever of unknown origin require urgent CT evaluation. Angioinvasive aspergillosis produces the characteristic halo sign in early disease, progressing to air crescent sign during neutrophil recovery. Cytomegalovirus pneumonia produces diffuse ground-glass opacities with small centrilobular nodules and septal thickening. Pneumocystis jirovecii pneumonia presents with diffuse bilateral ground-glass opacities, often with cyst formation and spontaneous pneumothorax. The distinction between these entities on CT, while suggestive, requires bronchoalveolar lavage or tissue biopsy for definitive diagnosis.^[47]

Hematopoietic stem cell transplant recipients face a temporal risk stratification for infectious complications. Pre-engraftment neutropenia predisposes to bacterial and fungal infections; early post-engraftment (days 30–100) carries risk of CMV and other viral pneumonias; late post-transplant (beyond day 100) sees increased risk of community-acquired pathogens and opportunistic infections related to chronic graft-versus-host disease and immunosuppressive therapy. CT protocols should be adapted to this temporal risk profile, with lower threshold for high-resolution CT during high-risk periods.^[48]

Pregnancy

Chest CT during pregnancy requires careful risk-benefit analysis. The fetal radiation dose from maternal chest CT is extremely low (less than 0.01 mGy), well below the threshold for deterministic effects. However, iodinated contrast crosses the placenta and should be used only when essential for maternal management. Non-contrast CT is preferred for pneumonia evaluation in pregnancy; contrast enhancement is reserved for suspected complications (abscess, empyema, pulmonary embolism) where the diagnostic benefit outweighs theoretical fetal risks.^[49]

The mouth-open breathing technique, which eliminates transient contrast interruption and reduces motion artifacts, is particularly valuable in pregnancy where breath-hold capacity is compromised by the gravid uterus elevating the diaphragm. Low-dose protocols with iterative reconstruction should be standard, and shielding of the gravid uterus, while of limited dosimetric benefit for chest CT, may provide psychological reassurance.

The critically ill and mechanically ventilated

Critically ill patients with suspected ventilator-associated pneumonia present unique imaging challenges. Transport to CT poses risks of hemodynamic instability, ventilator disconnect, and line displacement. Portable chest radiography remains first-line, but CT is indicated when radiography is inconclusive, when complications are suspected, or when clinical deterioration occurs despite appropriate therapy.^[50]

CT findings in ventilator-associated pneumonia include multifocal patchy or confluent consolidation, ground-glass opacities, and air bronchograms, often with pleural effusion. The distinction between ventilator-associated pneumonia and acute respiratory distress syndrome can be challenging, as both produce diffuse bilateral opacities. Focal consolidation, cavitation, and positive microbiological cultures favor pneumonia, while diffuse symmetric ground-glass opacities with relative sparing of the costophrenic angles favor ARDS. Quantitative CT assessment of non-aerated lung volume may help stratify severity and guide ventilator management.^[51]

Prone positioning, increasingly used for ARDS and severe COVID-19 pneumonia, alters the distribution of dependent atelectasis and may shift consolidation patterns. CT before and after proning can assess recruitment and guide duration of prone positioning. For patients unable to tolerate transport CT, lung ultrasound at the bedside provides real-time assessment of aeration, consolidation, and effusion without transport risks.

Elderly patients

Elderly patients with pneumonia present diagnostic challenges due to atypical clinical presentations, comorbidities, and baseline structural lung disease. Aspiration pneumonia is common due to dysphagia, gastroesophageal reflux, and impaired cough reflex. CT may reveal not only acute aspiration pneumonitis but also chronic changes including bronchiectasis, fibrosis, and traction bronchiectasis from recurrent aspiration events.

The distinction between community-acquired pneumonia and aspiration pneumonitis in elderly patients carries therapeutic implications. Community-acquired pneumonia typically requires antibiotic therapy directed at Streptococcus pneumoniae and atypical pathogens, while aspiration pneumonitis may resolve with supportive care alone unless secondary bacterial infection supervenes. CT patterns of dependent distribution, particularly in the posterior segments of upper lobes and superior segments of lower lobes, favor aspiration, while lobar or segmental consolidation favors typical bacterial pneumonia.^[52]

12. Artificial intelligence in pneumonia detection and quantification

Automated detection algorithms

Artificial intelligence has transformed pneumonia detection on chest CT, with convolutional neural networks and transformer-based architectures achieving detection accuracies exceeding 95% in validation cohorts.^[53] These algorithms can simultaneously detect, localize, and classify pneumonia patterns while quantifying severity, providing objective biomarkers that complement subjective radiologist interpretation.

Early AI systems focused on binary classification (pneumonia present or absent), but modern architectures provide pixel-level segmentation of consolidation, ground-glass opacities, and other patterns. This granular quantification enables precise measurement of disease extent, monitoring of temporal evolution, and prediction of clinical outcomes. For COVID-19 specifically, AI-based severity scores have demonstrated correlation with need for intensive care, mechanical ventilation, and mortality, outperforming traditional clinical severity scores in some studies.^[54]

Pattern classification and variant adaptation

Beyond simple detection, AI systems can classify pneumonia patterns into etiologic categories (bacterial, viral, fungal, aspiration) with moderate accuracy, though significant overlap limits standalone diagnostic utility. More promising is the application of AI to distinguish COVID-19 from other viral pneumonias, with some systems achieving area under the curve values of 0.85–0.92 for COVID-19 classification.^[55] However, these systems require continuous retraining as viral variants evolve and new pathogens emerge.

The integration of clinical data (demographics, symptoms, laboratory markers) with imaging features enables multimodal predictive modeling. A 2025 study demonstrated that combining CT radiomics with clinical variables improved prediction of Long COVID pulmonary sequelae compared to either modality alone, with the integrated model achieving an AUC of 0.89 for persistent fibrosis at 12 months.^[56]

Workflow integration and quality assurance

AI integration into clinical workflow requires careful attention to implementation science principles. Algorithms should flag suspicious cases for prioritized reporting, quantify disease burden for trending, and highlight subtle findings that may be overlooked during high-volume shifts. However, AI should augment rather than replace radiologist interpretation, with final diagnostic responsibility remaining with the interpreting physician. The radiologist-AI partnership model, where AI handles routine detection and quantification while radiologists focus on complex interpretation, clinical correlation, and communication, represents the most effective deployment strategy.

Quality assurance for AI systems includes monitoring of algorithm performance across diverse patient populations, imaging protocols, and scanner platforms. Drift detection algorithms should identify when AI performance degrades due to distribution shift, protocol changes, or software updates. Regulatory frameworks, including FDA clearance and CE marking, provide baseline safety assurance but do not replace institutional validation and ongoing monitoring. Every AI deployment should include a governance committee with representation from radiology, IT, clinical engineering, and quality improvement to ensure safe and effective integration into clinical practice.

AI integration into clinical workflow requires careful attention to implementation science principles. Algorithms should flag suspicious cases for prioritized reporting, quantify disease burden for trending, and highlight subtle findings that may be overlooked during high-volume shifts. However, AI should augment rather than replace radiologist interpretation, with final diagnostic responsibility remaining with the interpreting physician.

Quality assurance for AI systems includes monitoring of algorithm performance across diverse patient populations, imaging protocols, and scanner platforms. Drift detection algorithms should identify when AI performance degrades due to distribution shift, protocol changes, or software updates. Regulatory frameworks, including FDA clearance and CE marking, provide baseline safety assurance but do not replace institutional validation and ongoing monitoring.^[57]

13. Structured reporting and communication

Structured reporting templates improve communication quality, reduce omission errors, and facilitate quality assurance and research. For chest CT in pneumonia, a comprehensive template should include assessment of parenchymal abnormalities (distribution, pattern, extent), pleural findings, mediastinal evaluation, complications, comparison with prior imaging, and follow-up recommendations.

The RSNA chest CT structured reporting template, adapted for infectious indications, provides a standardized framework that ensures consistent documentation of critical findings. Key elements include: lobar involvement (right upper, right middle, right lower, left upper, left lower lingula, left lower); pattern (consolidation, ground-glass opacity, crazy-paving, tree-in-bud, nodules, reticulation); distribution (central, peripheral, peribronchovascular, random); complications (effusion, empyema, abscess, necrosis, pneumothorax); and severity quantification (percentage of lung involvement, CT severity score).^[58]

Communication of critical findings requires defined pathways and timeframes. Large multilobar consolidation, necrotizing pneumonia, tension pneumothorax, or massive hemoptysis require immediate verbal communication to the referring clinician. Empyema, abscess greater than 4 cm, or progressive disease despite therapy require communication within 1 hour. All other significant findings should be communicated within the standard reporting timeframe, with explicit documentation of communication method and recipient.

14. Quality metrics and continuous improvement

Effective quality improvement in chest CT for pneumonia requires systematic measurement of key performance indicators. Essential metrics include: protocol compliance rate (percentage of studies performed per standardized protocol); radiation dose metrics (CTDIvol, DLP, effective dose with comparison to diagnostic reference levels); report turnaround time (from image acquisition to final report); discrepancy rate (major and minor discrepancies between preliminary and final reports, or between radiology and clinical diagnosis); and outcome correlation (diagnostic accuracy compared to reference standard, clinical outcomes for patients with positive and negative CT).

The ACR CT Dose Index Registry provides benchmark data for comparison, enabling departments to identify outliers and target improvement interventions.^[59] Peer review programs, with randomized double-reading of a subset of cases, identify systematic interpretive errors and provide educational feedback. Multidisciplinary conferences linking radiology, pulmonology, infectious disease, and critical care teams improve diagnostic accuracy and therapeutic decision-making while fostering collaborative practice.

Radiation dose optimization should be a continuous process, with regular audit of dose distributions, identification of outlier studies, and feedback to technologists and radiologists. Dose reduction strategies including protocol refinement, iterative reconstruction, and deep learning denoising should be implemented systematically with validation of maintained diagnostic accuracy. The goal is not minimum dose but optimal dose: the lowest radiation exposure that achieves the diagnostic task with acceptable confidence.^[60]

15. Pitfall framework for radiographers, radiologists, and clinicians

Diagnostic errors in chest CT for pneumonia arise from distinct but interrelated failure modes that can be categorized by the professional group primarily responsible for prevention. A structured pitfall framework enables targeted quality improvement interventions, competency-based training, and systematic error reduction. Understanding these failure modes is essential for building resilient diagnostic systems that protect patients from harm.

Pitfalls for radiographers: technical failures

The most common radiographer pitfall is inadequate breath-holding, producing motion artifacts that degrade image quality and can simulate or obscure pneumonia. In patients with severe dyspnea who cannot achieve a 10-second breath-hold, rapid acquisition protocols or free-breathing techniques should be employed. Coaching techniques, including demonstration, practice breath-holds, and visual feedback, improve compliance and image quality. For patients with cognitive impairment or language barriers, simplified instructions and caregiver assistance are essential.

Incorrect patient positioning (arms not elevated, leading to beam-hardening artifacts across the lung apices) is another preventable error that should be addressed through standardized positioning checklists. Arms-down positioning produces severe streak artifacts that can obscure apical pathology, including Pancoast tumors, apical consolidation, and pneumothorax. Every positioning checklist should include explicit arm position verification.

Suboptimal slice thickness for the clinical indication represents a frequent protocol error. Standard 5 mm slices may miss subtle interstitial pneumonia, small nodules, or early ground-glass opacities; high-resolution CT with 1.0–1.25 mm slices should be employed when interstitial disease, immunocompromise, or COVID-19 pneumonia is suspected. Conversely, using high-resolution CT for all chest CTs unnecessarily increases dose and reconstruction time without diagnostic benefit for lobar consolidation or large effusions. Protocol selection should be indication-driven, with clear decision trees guiding slice thickness, reconstruction kernel, and dose settings.

Contrast timing errors in enhanced studies (scanning too early or too late relative to contrast arrival) produce suboptimal vascular opacification that can obscure pulmonary embolism or vascular complications of pneumonia. Test bolus or bolus tracking should be employed for all contrast-enhanced chest CTs, with region-of-interest placement in the main pulmonary artery or superior vena cava and threshold of 100–150 HU above baseline. The mouth-open breathing technique, originally developed for CTPA, eliminates transient interruption of contrast and should be considered for all contrast-enhanced chest CT acquisitions.

Pitfalls for radiologists: interpretive errors

The most consequential radiologist pitfall is failure to detect subtle pneumonia in high-risk populations (immunocompromised patients, early COVID-19, or interstitial pneumonia) where findings may be limited to subtle ground-glass opacities or small nodules. Every chest CT should be reviewed on lung windows (W1500/L−600) with thin-slice reconstructions, and the lung apices, bases, and retrocardiac regions should be scrutinized specifically, as these are common sites of missed pathology. The retrocardiac region is particularly vulnerable to oversight due to cardiac motion and beam-hardening artifacts.

Overcalling atelectasis as consolidation is a classic error, particularly in the lower lobes where dependent atelectasis is common. Prone imaging or correlation with prior imaging can differentiate true pneumonia (persistent in prone position) from atelectasis (shifts or resolves). Similarly, overcalling chronic changes as acute pneumonia (particularly in patients with COPD, fibrosis, or bronchiectasis) can lead to unnecessary antibiotic therapy. Comparison with prior imaging is essential for identifying new versus chronic abnormalities. When prior imaging is unavailable, clinical correlation with symptom duration, laboratory markers, and microbiological data can guide interpretation.

Failure to identify complications (abscess, empyema, necrotizing pneumonia, pneumothorax) deprives the clinical team of critical management information. Structured reporting templates should include explicit assessment for complications, with measurements of effusion size, abscess cavity dimensions, and pneumothorax extent. Failure to suggest alternative diagnoses when pneumonia is not the primary finding (pulmonary edema, hemorrhage, malignancy, pulmonary embolism) can lead to delayed or inappropriate treatment. The differential diagnosis section of every report should explicitly address the most likely alternatives and recommend appropriate follow-up or additional testing.

Pitfalls for clinicians: decision-making errors

The most dangerous clinician pitfall is failure to act on CT findings indicating severe pneumonia or complications. Large multilobar consolidation, necrotizing pneumonia, abscess greater than 4 cm, or empyema should trigger urgent intervention (antibiotic escalation, drainage, or surgical consultation), not routine ward management. The CURB-65 and PSI severity scores, while validated for community-acquired pneumonia, do not fully capture the prognostic information provided by CT findings such as necrosis, abscess, or multilobar involvement.

Over-reliance on CT negative results in patients with high clinical suspicion is another error; early pneumonia, particularly in immunocompromised patients, may be radiographically occult and require follow-up imaging or empiric therapy. The high negative predictive value of CT applies to standard-dose, properly timed studies; ultra-low-dose CT or studies performed too early in the disease course may yield false negatives.

Over-treatment of incidental findings (small subpleural nodules, minor atelectasis, or stable chronic changes reported as “possible pneumonia”) exposes patients to unnecessary antibiotics and their attendant risks. Clinical correlation with symptoms, laboratory markers (procalcitonin, CRP, WBC), and microbiological data is essential for confirming pneumonia diagnosis and guiding therapy. Failure to order follow-up imaging when pneumonia fails to resolve as expected (typically 4–6 weeks) can delay diagnosis of underlying malignancy, structural abnormality, or resistant infection. All pneumonia reports should include explicit follow-up recommendations with timing and modality.

16. Further reading

17. Dose optimization strategies: from ALARA to right-dose imaging

Tube voltage and current modulation

Tube voltage (kVp) selection profoundly impacts both radiation dose and iodine contrast enhancement. Lower kVp (80–100 kVp) increases photon energy relative to iodine K-edge, improving contrast-to-noise ratio while reducing dose. For chest CT in pneumonia, 100 kVp is standard for adults, with 80 kVp reserved for pediatric or very slim patients. Automatic tube current modulation (ATCM) adjusts mA along the z-axis and angularly based on patient attenuation, reducing dose by 20–40% compared to fixed techniques while maintaining image quality.^[61]

Reference mAs settings should be tailored to patient size using the effective diameter calculated from lateral and AP scout images. Size-specific dose estimates (SSDE) provide more accurate dose characterization than CTDIvol alone, accounting for patient size variation. Departments should establish size-based protocol libraries with predefined kVp, reference mAs, and reconstruction parameters for small, medium, and large adult categories, with further stratification for pediatric patients by weight or age.

Iterative and deep learning reconstruction

Iterative reconstruction algorithms have evolved through multiple generations, from hybrid iterative reconstruction (combining filtered back projection with noise reduction) to model-based iterative reconstruction (MBIR) and now deep learning reconstruction (DLR). Each generation offers improved noise reduction at lower dose, with DLR achieving the most dramatic dose reductions while preserving fine parenchymal detail.^[62]

Deep learning reconstruction networks are trained on pairs of low-dose and high-dose images, learning to map noisy low-dose acquisitions to high-quality outputs. Unlike traditional iterative reconstruction, which can produce blotchy or plastic-like textures at aggressive settings, DLR preserves natural image texture while reducing noise. For pneumonia imaging, where detection of subtle ground-glass opacities depends on both noise level and texture fidelity, DLR represents a paradigm shift enabling ultra-low-dose protocols without diagnostic compromise.

Validation studies for DLR in chest CT have demonstrated non-inferiority to standard-dose filtered back projection for detection of ground-glass opacities, consolidation, nodules, and interstitial changes at doses 50–80% lower than conventional protocols.^[63] However, each vendor’s DLR algorithm has distinct characteristics, and institutions should perform local validation before clinical implementation, particularly for subtle findings where texture preservation is critical.

Photon-counting CT

Photon-counting CT detectors, now entering clinical practice, offer fundamental advantages over conventional energy-integrating detectors: improved spatial resolution, reduced electronic noise, enhanced iodine contrast, and simultaneous multi-energy data acquisition. For pneumonia imaging, the improved spatial resolution may better characterize subtle interstitial changes, while multi-energy data enables iodine mapping for perfusion assessment and virtual non-contrast images that reduce the need for pre-contrast scans.^[64]

Early clinical experience suggests dose reductions of 30–50% are achievable with photon-counting CT while maintaining or improving image quality compared to conventional detectors. The technology is particularly promising for pediatric and follow-up imaging, where cumulative dose concerns are paramount. However, widespread adoption awaits cost reduction, vendor diversity, and long-term clinical validation across the full spectrum of thoracic indications.

Contrast media safety in pneumonia imaging

Iodinated contrast media administration for chest CT carries risks that must be balanced against diagnostic benefit. Acute kidney injury, while historically overstated, remains a concern in patients with pre-existing renal dysfunction, dehydration, or concurrent nephrotoxic medications. The American College of Radiology Manual on Contrast Media recommends assessing renal function in patients with eGFR less than 30 mL/min/1.73m² before contrast administration, with individualized risk stratification for those with eGFR 30–44 mL/min/1.73m².^[65]

Contrast-induced allergic reactions range from mild urticaria to life-threatening anaphylaxis. Pre-medication with corticosteroids and antihistamines reduces but does not eliminate risk in patients with prior reactions. The use of low-osmolar or iso-osmolar contrast agents further reduces reaction rates. For patients with documented severe contrast allergy where contrast-enhanced CT is essential, pre-medication protocols and availability of emergency resuscitation equipment are mandatory.^[66]

Venous air embolism, while rare, represents a potentially catastrophic complication of contrast injection. The dual-check-valve design of SATLine patient lines eliminates this risk by preventing air entry and ensuring complete bubble evacuation before contrast reaches the patient. Every contrast-enhanced CT protocol should include systematic air purging, line inspection, and pressure monitoring to detect line disconnections or extravasation before they cause patient harm. For a comprehensive analysis of air embolism prevention in contrast-enhanced imaging, see our dedicated article on venous air embolism in CT and MRI.^[67]

Structured follow-up protocols

Follow-up imaging after pneumonia serves multiple purposes: confirmation of resolution, detection of underlying malignancy or structural abnormality, and assessment of complications. Standard practice recommends follow-up chest radiography at 4–6 weeks for all hospitalized patients and those with risk factors for underlying malignancy (age greater than 50, smoking history, weight loss, hemoptysis). CT follow-up is reserved for patients with persistent symptoms, radiographic non-resolution, or high clinical suspicion for malignancy.^[68]

For COVID-19 pneumonia, follow-up CT protocols are evolving. The 2025 international consensus recommends low-dose chest CT at 3 months for patients with persistent respiratory symptoms, with further imaging at 6 and 12 months if abnormalities persist. Quantitative CT metrics including well-aerated lung volume, fibrosis extent, and traction bronchiectasis score provide objective biomarkers for disease trajectory and treatment response. Patients with persistent fibrotic changes beyond 12 months may require ongoing surveillance and referral to interstitial lung disease specialists for consideration of antifibrotic therapy.^[11]

The integration of imaging follow-up with pulmonary function testing, six-minute walk testing, and patient-reported outcome measures enables comprehensive assessment of Long COVID cardiopulmonary sequelae. Multidisciplinary follow-up clinics linking radiology, pulmonology, cardiology, and rehabilitation medicine provide coordinated care for this complex patient population, with imaging serving as a critical biomarker for disease progression and treatment response.

18. Conclusion

Chest computed tomography has established itself as the indispensable imaging modality for pneumonia diagnosis when plain radiography is inconclusive, when complications are suspected, or when high-risk patients require definitive exclusion of pulmonary infection. The evolution from standard-dose CT to low-dose, high-resolution, and AI-augmented protocols has transformed the diagnostic landscape, enabling rapid, accurate, and safe evaluation across the full spectrum of pneumonia etiologies (from community-acquired bacterial infection to COVID-19 variants and their enduring Long COVID sequelae).

The seven critical protocol steps outlined in this review (optimized scanning technique with appropriate slice thickness and reconstruction; radiation dose minimization through low-kVp, low-mAs, and advanced reconstruction algorithms; pattern recognition for bacterial, viral, fungal, and aspiration etiologies; COVID-19-specific imaging evolution and variant adaptation; Long COVID cardiopulmonary surveillance; special population modifications for children, immunocompromised patients, pregnant patients, and the critically ill; and AI-integrated quality assurance and detection) collectively define the standard of care for modern thoracic imaging in pneumonia.

The integration of structured reporting templates, quality metrics dashboards, and multidisciplinary audit programs ensures that protocol optimization translates into measurable patient benefit. Departments that systematically track protocol compliance, radiation dose distributions, report turnaround times, and diagnostic accuracy create feedback loops that drive continuous improvement. The most successful radiology departments view chest CT for pneumonia not as a commodity service but as a specialized diagnostic procedure requiring the same rigor and standardization as cardiac CT angiography or oncologic staging protocols.

The mouth-open breathing technique, while developed for CTPA, has cross-applicability to all breath-hold chest CT acquisitions, eliminating the transient interruption of contrast and motion artifacts that degrade image quality. Similarly, the patient-specific contrast formula and exponentially decelerated contrast delivery, while designed for vascular imaging, exemplify the mathematical precision that should characterize all contrast-enhanced protocols, including those for complicated pneumonia requiring vascular or cardiac evaluation.

Underpinning all of these advances is the fundamental requirement for reliable, high-performance imaging infrastructure. The SATLine patient lines with dual check valves, SATSyringe high-pressure syringes, and multi-use 24-hour sets provide the validated, bubble-free fluid paths and standardized consumables that maintain contrast integrity and protocol consistency across all chest CT applications. Without this foundation of dependable equipment and rigorous quality assurance, even the most sophisticated protocol optimization cannot achieve its diagnostic potential.

For radiographers, radiologists, and hospital administrators, the imperative is clear: pneumonia imaging should be approached with the same protocol-driven mentality that defines vascular and cardiac CT. The convergence of advanced hardware, intelligent software, and standardized consumables creates an unprecedented opportunity to elevate the quality, safety, and efficiency of chest CT for pneumonia across every healthcare setting, from tertiary academic centers to community hospitals and resource-limited environments. Departments that invest in standardized chest CT workflows (from patient positioning and breath-hold coaching to reconstruction algorithms, structured reporting, and AI-assisted quality assurance) do not merely improve image quality metrics. They protect patients from missed diagnoses, delayed treatment, unnecessary radiation exposure, and preventable complications, fulfilling the core professional mandate of evidence-based, patient-centred radiological practice. In an era of increasing imaging demand, workforce constraints, and quality expectations, protocol excellence in chest CT for pneumonia is not optional but essential.

19. References

1. [1] GBD 2019 Lower Respiratory Infections Collaborators. (2022). Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: Results from the GBD 2019 study. The Lancet Infectious Diseases, 22(11), 1623–1647. https://doi.org/10.1016/S1473-3099(22)00533-9
2. [2] Wunderink, R. G., & Waterer, G. W. (2014). Community-acquired pneumonia. The New England Journal of Medicine, 370(6), 543–551. https://doi.org/10.1056/NEJMcp1214862
3. [3] Self, W. H., Courtney, D. M., McNaughton, C. D., Wunderink, R. G., & Kline, J. A. (2013). High discordance of chest X-ray and computed tomography for detection of pulmonary opacities in ED patients: Implications for diagnosing pneumonia. The American Journal of Medicine, 126(6), 541.e1–541.e7. https://doi.org/10.1016/j.amjmed.2012.10.026
4. [4] Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., Cui, J., Xu, W., Yang, Y., Fayad, Z. A., Jacobi, A., Li, K., Li, S., & Shan, H. (2020). CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology, 295(1), 202–207. https://doi.org/10.1148/radiol.2020200230
5. [5] Han, Y., Wang, Z., Li, X., & Zhong, Z. (2025). Differences in chest imaging between Omicron and non–Omicron coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. BMC Infectious Diseases, 25(1), 631. https://doi.org/10.1186/s12879-025-11032-z
6. [6] Xu, W., Zhao, J., Wang, T., Lai, J., Wang, J., Jiang, F., Wang, C., & Fu, G. (2026). Clinical and CT image features for survival prediction in severe pneumonia during the SARS-CoV-2 Omicron wave. Frontiers in Medicine, 12, Article 1663710. https://doi.org/10.3389/fmed.2025.1663710
7. [7] Andronikou, S., Lambert, E., Halton, J., Hilder, L., & Crumley, I. (2024). Imaging of acute complications of community-acquired pneumonia in children. Children, 11(1), 122. https://doi.org/10.3390/children11010122
8. [8] Rawat, M., Saade, C., Rawat, U., Ahlawat, S., Obeid, R., & Ghosn, Y. (2021). Radiation dose reduction considerations and imaging patterns of ground glass opacities in coronavirus: Risk of over exposure in computed tomography. La Radiologia Medica, 126(2), 307–311. https://doi.org/10.1007/s11547-020-01272-9
9. [9] Dangis, A., Gieraerts, C., De Bruecker, Y., Janssen, L., Valgaeren, H., Obbels, D., Gillis, M., Van Cauteren, T., Verbeke, P., & De Brucker, N. (2021). Ultra-low-dose chest CT performance for the detection of viral pneumonia patterns during the COVID-19 outbreak period: A monocentric, retrospective, observational cohort study. Quantitative Imaging in Medicine and Surgery, 11(7), 2976–2987. https://doi.org/10.21037/qims-20-1336
10. [10] Slasky, B. S., & Walker, C. M. (2025). Denoised ultra-low-dose chest CT to assess pneumonia in immunocompromised patients. Radiology: Cardiothoracic Imaging, 7(2), e240189. https://doi.org/10.1148/ryct.240189
11. [11] Larici, R., Calandriello, L., Lucci, S., D’Angelo, E., Agliata, G., Montanari, F., Schinzari, G., Sverzellati, N., & Maffessanti, M. (2025). Best practice: International multisociety consensus statement for post–COVID-19 residual abnormalities on chest CT scans. Radiology. https://doi.org/10.1148/radiol.243374
12. [12] Franquet, T., Jeong, Y. J., Lam, K. S., Chung, M. J., Lee, K. S., Goo, J. M., & Müller, N. L. (2018). Radiographic and CT features of viral pneumonia. RadioGraphics, 38(3), 719–739. https://doi.org/10.1148/rg.2018170048
13. [13] Marchiori, E., Zanetti, G., Hochhegger, B., & Irion, K. L. (2019). Pulmonary invasive fungal disease and bacterial pneumonia: Distinctive CT patterns in immunocompromised patients. American Journal of Translational Research, 11(7), 4239–4247. https://pmc.ncbi.nlm.nih.gov/articles/PMC6684894
14. [14] Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., Tao, Q., Sun, Z., & Xia, L. (2020). Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology, 296(2), E32–E40. https://doi.org/10.1148/radiol.2020200642
15. [15] Prokop, M., van Everdingen, W., van Rees Vellinga, T., Quarles van Ufford, H., Stöger, L., Beenen, L., van der Werf, T. S., van den Berk, I. A. H., Geurts, B., & van Ginneken, B. (2020). CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19—Definition and evaluation. Radiology, 296(2), E97–E104. https://doi.org/10.1148/radiol.2020201473
16. [16] Francone, M., Iafrate, F., Masci, G. M., Coco, S., Cilia, F., Manganaro, L., Panebianco, V., Andreoli, C., Colaiacomo, M. C., Zingaropoli, M. A., Ciardi, M. R., Mollura, F. G., & Laghi, A. (2020). Chest CT score in COVID-19 patients: Correlation with disease severity and short-term prognosis. European Radiology, 30(12), 6808–6817. https://doi.org/10.1007/s00330-020-07033-y
17. [17] Cavalcanti, L. G., Pereira, S. A., de Souza, R. M., & de Melo, A. V. (2026). Long-term pulmonary function and radiologic abnormalities up to 3 years after COVID-19: A systematic review and meta-analysis. Korean Journal of Radiology. https://doi.org/10.3348/kjr.2025.1272
18. [18] Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023). Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133–146. https://doi.org/10.1038/s41579-022-00846-2
19. [19] Larici, R., Calandriello, L., Lucci, S., D’Angelo, E., Agliata, G., Montanari, F., Schinzari, G., Sverzellati, N., & Maffessanti, M. (2025). Best practice: International multisociety consensus statement for post–COVID-19 residual abnormalities on chest CT scans. Radiology. https://doi.org/10.1148/radiol.243374
20. [20] Bell, L. C., et al. (2025). Persistent cardiovascular and pulmonary abnormalities in Long COVID patients. Mount Sinai Reports.
21. [21] Xie, Y., Xu, E., Bowe, B., & Al-Aly, Z. (2022). Long-term cardiovascular outcomes of COVID-19. Nature Medicine, 28(3), 583–590. https://doi.org/10.1038/s41591-022-01689-3
22. [22] Trivieri, M. G., Spagnolo, P., & Skali, H. (2025). Prevalence of persistent cardiovascular and pulmonary abnormalities on PET/MRI and DECT imaging in long COVID patients. Journal of Nuclear Medicine, 66(7), 1126–1134. https://doi.org/10.2967/jnumed.124.268980
23. [23] Mount Sinai. (2025). Persistent lung and vascular inflammation in mild to moderate COVID-19 survivors detected by ¹⁸F-FDG PET/CT. Mount Sinai Research Reports.
24. [24] SNMMI. (2025). Abnormal Long COVID PET/MR findings linked to future cardiac and pulmonary diseases. Society of Nuclear Medicine and Molecular Imaging News.
25. [25] Kim, W. S., Moon, W. K., Cho, S. H., Kim, S. O., Yeon, K. M., & Chi, J. G. (1997). Round pneumonia: Imaging findings in a large series of children. Pediatric Radiology, 27(2), 163–167. https://doi.org/10.1007/s002470050089
26. [26] Sawicki, G. S., Lu, F. L., Valim, C., Cleveland, R. H., & Colin, A. A. (2008). Necrotising pneumonia is an increasingly detected complication of pneumonia in children. European Respiratory Journal, 31(6), 1285–1291. https://doi.org/10.1183/09031936.00099807
27. [27] Sahn, S. A. (2007). Diagnosis and management of parapneumonic effusions and empyema. Clinical Infectious Diseases, 45(11), 1480–1486. https://doi.org/10.1086/522996
28. [28] Islam, N., Ebrahimzadeh, S., Salameh, J. P., Kazi, S., Fabiano, N., Treanor, L., Absi, M., Hallgrimson, Z., Leeflang, M. M. G., Hooft, L., van der Pol, C. B., Prager, R., McInnes, M. D. F., & Moher, D. (2021). Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database of Systematic Reviews, 3(3), CD013639. https://doi.org/10.1002/14651858.CD013639.pub4
29. [29] Xu, B., Xing, Y., Peng, J., Zheng, Z., Tang, W., Sun, Y., Xu, C., & Peng, F. (2020). Chest CT for detecting COVID-19: A systematic review and meta-analysis of diagnostic accuracy. European Radiology, 30(10), 5720–5727. https://doi.org/10.1007/s00330-020-06934-2
30. [30] Claessens, Y. E., Debray, M. P., Tubach, F., Brun, A. L., Rammaert, B., Hausfater, P., Naccache, J. M., & Sanchez, O. (2014). Chest CT scan in acute exacerbation of COPD: A systematic review. International Journal of Chronic Obstructive Pulmonary Disease, 9, 231–243. https://doi.org/10.2147/COPD.S58642
31. [31] Albaum, M. N., Hill, P. C., Murphy, S. A., Li, Y. H., Fuhrman, C. R., Britton, C. A., & Charland, S. L. (1996). Interobserver reliability of the chest radiograph in community-acquired pneumonia. Chest, 110(2), 343–350. https://doi.org/10.1378/chest.110.2.343
32. [32] Kanne, J. P. (2020). Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: Key points for the radiologist. Radiology, 295(1), 16–17. https://doi.org/10.1148/radiol.2020200241
33. [33] Sudre, C. H., Murray, B., Varsavsky, T., Graham, M. S., Penfold, R. S., Bowyer, R. C., Pujol, J. C., Klaser, K., Antonelli, M., Canas, L. S., Molteni, E., Modat, M., Jorge, J. D., May, A., & Steves, C. J. (2021). Attributes and predictors of long COVID. Nature Medicine, 27(4), 626–631. https://doi.org/10.1038/s41591-021-01292-y
34. [34] Huang, L., Yao, Q., Gu, X., Wang, Q., Ren, L., Wang, Y., Hu, P., Guo, L., Liu, M., Xu, J., Zhang, L., & Liu, L. (2021). 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. The Lancet, 398(10302), 747–758. https://doi.org/10.1016/S0140-6736(21)01755-4
35. [35] Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., Ray, S. M., Thompson, D. L., Wilson, L. E., & Fridkin, S. K. (2014). Multistate point-prevalence survey of health care–associated infections. The New England Journal of Medicine, 370(13), 1198–1208. https://doi.org/10.1056/NEJMoa1306801
36. [36] Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997). A prediction rule to identify low-risk patients with community-acquired pneumonia. The New England Journal of Medicine, 336(4), 243–250. https://doi.org/10.1056/NEJM199701233360402
37. [37] Lim, W. S., van der Eerden, M. M., Laing, R., Boersma, W. G., Karalus, N., Town, G. I., Lewis, S. A., & Macfarlane, J. T. (2003). Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax, 58(5), 377–382. https://doi.org/10.1136/thorax.58.5.377
38. [38] Colombi, D., Bodini, F. C., Petrini, M., Maffi, G., Morelli, N., Milanese, G., Silva, M., & Sverzellati, N. (2020). Well-aerated lung on admitting chest CT to predict adverse outcome in COVID-19 pneumonia. Radiology, 296(2), E86–E96. https://doi.org/10.1148/radiol.2020201433
39. [39] Ramirez, J. A., & Wiemken, T. L. (2020). Clinical practice guideline for the diagnosis and treatment of community-acquired pneumonia. Clinical Infectious Diseases, 71(4), e45–e52. https://doi.org/10.1093/cid/ciaa429
40. [40] American College of Radiology. (2024). ACR Appropriateness Criteria: Acute respiratory illness in immunocompetent patients. https://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria
41. [41] European Commission. (2014). European guidelines on quality criteria for diagnostic radiographic images in paediatrics. Luxembourg: Publications Office of the European Union.
42. [42] Kalra, M. K., Maher, M. M., Toth, T. L., Hamberg, L. M., Blake, M. A., Shepard, J. A., & Saini, S. (2004). Strategies for CT radiation dose optimization. Radiology, 230(3), 619–628. https://doi.org/10.1148/radiol.2303021726
43. [43] Willemink, M. J., Koszek, W. A., Hardell, C., Wu, J., Fleischmann, D., Harvey, H., Folio, L. R., & Rubin, D. L. (2020). Preparing medical imaging data for machine learning. Radiology, 295(1), 4–15. https://doi.org/10.1148/radiol.2020192224
44. [44] Chen, H., Zhang, Y., Kalra, M. K., Lin, F., Chen, Y., Liao, P., Zhou, J., & Wang, G. (2017). Low-dose CT with a residual encoder-decoder convolutional neural network. IEEE Transactions on Medical Imaging, 36(12), 2524–2535. https://doi.org/10.1109/TMI.2017.2715284
45. [45] Kang, E., Min, J., & Ye, J. C. (2017). A deep convolutional neural network using directional wavelets for low-dose X-ray CT reconstruction. Medical Physics, 44(10), e360–e375. https://doi.org/10.1002/mp.12344